Cargando…

Small fiber neuropathy: Swiss cohort characterization

INTRODUCTION/AIM: There is currently insufficient clinical and epidemiological data concerning small fiber neuropathy (SFN). This research analyzes data from medical records to determine epidemiology, demographics, clinical characteristics and etiology of SFN. METHODS: This is a retrospective, obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitzi, Lorena M., Lehnick, Dirk, Wilder‐Smith, Einar P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453953/
https://www.ncbi.nlm.nih.gov/pubmed/34075618
http://dx.doi.org/10.1002/mus.27340
_version_ 1784570387775881216
author Bitzi, Lorena M.
Lehnick, Dirk
Wilder‐Smith, Einar P.
author_facet Bitzi, Lorena M.
Lehnick, Dirk
Wilder‐Smith, Einar P.
author_sort Bitzi, Lorena M.
collection PubMed
description INTRODUCTION/AIM: There is currently insufficient clinical and epidemiological data concerning small fiber neuropathy (SFN). This research analyzes data from medical records to determine epidemiology, demographics, clinical characteristics and etiology of SFN. METHODS: This is a retrospective, observational study of sequential patients diagnosed with definite SFN (typical clinical features, normal nerve conduction studies, abnormal epidermal nerve fiber density) from the end of November 2016 to the middle of July 2019 at the Cantonal Hospital Lucerne, central Switzerland. RESULTS: A total of 84 patients (64.3% female) with a mean age of 54.7 y were analyzed. Symptoms had been present in patients for an average of 4.8 y when entering the study. A length dependent clinical pattern was seen in 79.8%. All patients had sensory discomfort. Etiology could not be determined in 35.7% of patients, who were diagnosed with idiopathic SFN; 34.5% of patients had an apparently autoimmune SFN, followed by14.3% of patients with metabolic causes. The estimated incidence was at least 4.4 cases/100.000 inhabitants/y. The minimum prevalence was 131.5 cases/100.000 inhabitants. DISCUSSION: This study indicates significant incidence and prevalence rates of SFN in Switzerland. SFN can vary greatly in its symptoms and severity. Extensive work‐up resulted in two thirds of the patients being assigned an etiological association. The largest group of patients could not be etiologically defined, underlining the importance of further research on etiologic identification. We expect increased awareness of the developing field of SFN.
format Online
Article
Text
id pubmed-8453953
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-84539532021-09-27 Small fiber neuropathy: Swiss cohort characterization Bitzi, Lorena M. Lehnick, Dirk Wilder‐Smith, Einar P. Muscle Nerve Clinical Research Articles INTRODUCTION/AIM: There is currently insufficient clinical and epidemiological data concerning small fiber neuropathy (SFN). This research analyzes data from medical records to determine epidemiology, demographics, clinical characteristics and etiology of SFN. METHODS: This is a retrospective, observational study of sequential patients diagnosed with definite SFN (typical clinical features, normal nerve conduction studies, abnormal epidermal nerve fiber density) from the end of November 2016 to the middle of July 2019 at the Cantonal Hospital Lucerne, central Switzerland. RESULTS: A total of 84 patients (64.3% female) with a mean age of 54.7 y were analyzed. Symptoms had been present in patients for an average of 4.8 y when entering the study. A length dependent clinical pattern was seen in 79.8%. All patients had sensory discomfort. Etiology could not be determined in 35.7% of patients, who were diagnosed with idiopathic SFN; 34.5% of patients had an apparently autoimmune SFN, followed by14.3% of patients with metabolic causes. The estimated incidence was at least 4.4 cases/100.000 inhabitants/y. The minimum prevalence was 131.5 cases/100.000 inhabitants. DISCUSSION: This study indicates significant incidence and prevalence rates of SFN in Switzerland. SFN can vary greatly in its symptoms and severity. Extensive work‐up resulted in two thirds of the patients being assigned an etiological association. The largest group of patients could not be etiologically defined, underlining the importance of further research on etiologic identification. We expect increased awareness of the developing field of SFN. John Wiley & Sons, Inc. 2021-06-16 2021-09 /pmc/articles/PMC8453953/ /pubmed/34075618 http://dx.doi.org/10.1002/mus.27340 Text en © 2021 The Authors. Muscle & Nerve published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Research Articles
Bitzi, Lorena M.
Lehnick, Dirk
Wilder‐Smith, Einar P.
Small fiber neuropathy: Swiss cohort characterization
title Small fiber neuropathy: Swiss cohort characterization
title_full Small fiber neuropathy: Swiss cohort characterization
title_fullStr Small fiber neuropathy: Swiss cohort characterization
title_full_unstemmed Small fiber neuropathy: Swiss cohort characterization
title_short Small fiber neuropathy: Swiss cohort characterization
title_sort small fiber neuropathy: swiss cohort characterization
topic Clinical Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453953/
https://www.ncbi.nlm.nih.gov/pubmed/34075618
http://dx.doi.org/10.1002/mus.27340
work_keys_str_mv AT bitzilorenam smallfiberneuropathyswisscohortcharacterization
AT lehnickdirk smallfiberneuropathyswisscohortcharacterization
AT wildersmitheinarp smallfiberneuropathyswisscohortcharacterization